JP4702361B2 - ピリジル非芳香族含窒素ヘテロ環−１−カルボン酸エステル誘導体 - Google Patents

ピリジル非芳香族含窒素ヘテロ環−１−カルボン酸エステル誘導体 Download PDF

Info

Publication number
JP4702361B2
JP4702361B2 JP2007503689A JP2007503689A JP4702361B2 JP 4702361 B2 JP4702361 B2 JP 4702361B2 JP 2007503689 A JP2007503689 A JP 2007503689A JP 2007503689 A JP2007503689 A JP 2007503689A JP 4702361 B2 JP4702361 B2 JP 4702361B2
Authority
JP
Japan
Prior art keywords
solution
added
etoac
carboxylate
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2007503689A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2006088075A1 (ja
Inventor
孝拓 石井
隆史 菅根
純 前田
史恵 楢▲ざき▼
昭夫 掛札
健太郎 佐藤
竜久 ▲高▼橋
隆俊 金山
親 齋藤
鈴木丈太郎
千里 金井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Priority to JP2007503689A priority Critical patent/JP4702361B2/ja
Publication of JPWO2006088075A1 publication Critical patent/JPWO2006088075A1/ja
Application granted granted Critical
Publication of JP4702361B2 publication Critical patent/JP4702361B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2007503689A 2005-02-17 2006-02-16 ピリジル非芳香族含窒素ヘテロ環−１−カルボン酸エステル誘導体 Active JP4702361B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007503689A JP4702361B2 (ja) 2005-02-17 2006-02-16 ピリジル非芳香族含窒素ヘテロ環−１−カルボン酸エステル誘導体

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2005040197 2005-02-17
JP2005040197 2005-02-17
JP2005303065 2005-10-18
JP2005303065 2005-10-18
PCT/JP2006/302698 WO2006088075A1 (ja) 2005-02-17 2006-02-16 ピリジル 非芳香族含窒素ヘテロ環－１－カルボン酸エステル誘導体
JP2007503689A JP4702361B2 (ja) 2005-02-17 2006-02-16 ピリジル非芳香族含窒素ヘテロ環−１−カルボン酸エステル誘導体

Publications (2)

Publication Number Publication Date
JPWO2006088075A1 JPWO2006088075A1 (ja) 2008-07-03
JP4702361B2 true JP4702361B2 (ja) 2011-06-15

Family

ID=36916476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007503689A Active JP4702361B2 (ja) 2005-02-17 2006-02-16 ピリジル非芳香族含窒素ヘテロ環−１−カルボン酸エステル誘導体

Country Status (20)

Country Link
US (3) US7919495B2 (enExample)
EP (2) EP1849773B1 (enExample)
JP (1) JP4702361B2 (enExample)
KR (3) KR101063663B1 (enExample)
CN (1) CN101160287B (enExample)
AU (3) AU2006215080B2 (enExample)
BR (1) BRPI0608205B8 (enExample)
CA (1) CA2598294C (enExample)
CY (2) CY1114709T1 (enExample)
DK (2) DK1849773T3 (enExample)
ES (2) ES2528674T3 (enExample)
IL (1) IL184998A (enExample)
MX (1) MX2007010076A (enExample)
NO (1) NO20074697L (enExample)
PL (2) PL1849773T3 (enExample)
PT (2) PT2607362E (enExample)
RU (3) RU2376289C2 (enExample)
SI (2) SI2607362T1 (enExample)
TW (3) TWI385152B (enExample)
WO (1) WO2006088075A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
BRPI0613505A2 (pt) * 2005-06-30 2011-01-11 Prosidion Ltd agonistas de gpcr
US7541359B2 (en) 2005-06-30 2009-06-02 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
NZ564758A (en) * 2005-06-30 2011-03-31 Prosidion Ltd G-protein coupled receptor agonists
WO2007098086A2 (en) * 2006-02-17 2007-08-30 Avalon Pharmaceuticals Hydroxypiperidine derivatives and uses thereof
CA2665804A1 (en) * 2006-08-23 2008-02-28 Astellas Pharma Inc. Urea compound or salt thereof
GEP20125425B (en) 2006-10-18 2012-03-26 Pfizer Prod Inc Biaryl ether urea compounds
CA2687931C (en) * 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
BRPI0815591B8 (pt) 2007-08-22 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, e, uso de um composto.
EA018703B1 (ru) * 2008-04-07 2013-10-30 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
WO2009143404A1 (en) * 2008-05-23 2009-11-26 Wyeth Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression
TWI434842B (zh) * 2008-07-14 2014-04-21 Astellas Pharma Inc Azole compounds
TW201031652A (en) 2008-11-06 2010-09-01 Astellas Pharma Inc Carbamic acid ester compound or salt thereof
CN103724328B (zh) 2008-12-19 2015-10-14 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
PL2513093T3 (pl) 2009-12-17 2015-03-31 Centrexion Therapeutics Corp Nowi antagoniści receptora CCR2 i ich zastosowanie
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
AU2010344973B2 (en) * 2010-02-05 2016-06-16 Merck Patent Gmbh Hetaryl-[1,8]naphthyridine derivatives
AU2011218492B2 (en) 2010-02-18 2014-11-13 Astrazeneca Ab New crystalline form of a cyclopropyl benzamide derivative
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
TW201206440A (en) * 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
JP2013147430A (ja) * 2010-04-28 2013-08-01 Astellas Pharma Inc 夜間頻尿の予防又は治療剤
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
JP5636094B2 (ja) 2010-05-25 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体アンタゴニスト
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
SG11201500498SA (en) * 2012-07-24 2015-03-30 Bial Portela & Ca Sa Urea compounds and their use as enzyme inhibitors
DE102012018115A1 (de) 2012-09-13 2014-03-13 Matthias Lehr Aryl-N-(arylalkyl)carbamate als Hemmstoffe der Fatty Acid Amide Hydrolase
GB201218084D0 (en) * 2012-10-09 2012-11-21 Univ Aston Novel compounds and methods for use in medicine
HUP1300139A2 (en) 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
DE102013016573A1 (de) 2013-10-04 2015-04-09 Matthias Lehr 1-Tetrazolylpropan-2-one als Inhibitoren von cytosolischer Phospholipase A2 und Fatty Acid Amide Hydrolase, insbesondere geeignet zur topischen Anwendung
MA41168A (fr) * 2014-12-17 2017-10-24 Acraf Nouveaux composés antibactériens
AU2016287584B2 (en) 2015-07-02 2020-03-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
NZ756915A (en) * 2017-03-13 2023-03-31 Lundbeck La Jolla Research Center Inc Dual magl and faah inhibitors
SG10201802129QA (en) * 2017-07-05 2019-02-27 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US11597715B2 (en) 2018-01-11 2023-03-07 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease
MY208901A (en) * 2018-09-13 2025-06-09 Celgene Corp Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof
CA3127590A1 (en) * 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
AU2020391467A1 (en) 2019-11-29 2022-06-23 Autobahn Therapeutics, Inc. Novel thyromimetics
CA3268476A1 (en) * 2022-09-30 2024-04-04 Us Health Partial dopamine D3/D2 receptor agonists for the treatment of neuropsychiatric disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04261157A (ja) * 1990-09-27 1992-09-17 Hoechst Roussel Pharmaceut Inc 置換−４−アミノ−３−ピリジノール、その製造法および医薬としてのその使用
JPH09510974A (ja) * 1994-03-25 1997-11-04 バーテクス ファーマシューティカルズ インコーポレイテッド 多剤耐性のモディファイアーとしての新規カルバメートおよびウレア
JPH09511764A (ja) * 1995-01-11 1997-11-25 三進製藥株式會社 新規ピペラジン誘導体、その製造方法及びそれを含有する組成物
JP2001503778A (ja) * 1996-11-13 2001-03-21 バーテックス ファーマシューティカルズ インコーポレイテッド 神経栄養因子と組み合わせてｆｋｂｐ１２に関するアフィニティを有する化合物を用いて神経突起の成長を刺激する方法および組成物
JP2002541109A (ja) * 1999-04-01 2002-12-03 ファイザー・プロダクツ・インク ソルビトールデヒドロゲナーゼ阻害薬としてのアミノピリミジン

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2146254C1 (ru) * 1996-06-29 2000-03-10 Самдзин Фармасьютикал Ко., Лтд. Производные пиперазина и способ их получения
US5870472A (en) * 1996-11-12 1999-02-09 General Instrument Corporation Dynamic relocation of the service data channel
IL137517A0 (en) 1998-01-27 2001-07-24 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl factor xa inhibitors
HUP0203375A3 (en) 1999-07-28 2005-03-29 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl compounds
EP1337271B1 (en) 2000-11-30 2004-11-03 Pfizer Products Inc. Combination of gaba agonists and sorbitol dehydrogenase inhibitors
ATE348829T1 (de) 2001-02-06 2007-01-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
PL373156A1 (en) 2001-12-14 2005-08-22 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
JP2003192659A (ja) 2001-12-26 2003-07-09 Bayer Ag フェニル尿素誘導体
AU2002358700A1 (en) 2001-12-26 2003-07-15 Bayer Aktiengesellschaft Urea derivatives as vr1- antagonists
PL373970A1 (en) 2002-02-08 2005-09-19 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors
FR2843964B1 (fr) 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
MXPA05003715A (es) * 2002-10-07 2005-09-30 Univ California Modulacion de ansiedad a traves de bloqueo de hidrolisis de anandamida.
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2004111004A1 (en) 2003-06-12 2004-12-23 Novo Nordisk A/S Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase
MXPA05013226A (es) 2003-06-12 2006-03-09 Novo Nordisk As Carbamatos de piperidina sustituidos, para el uso como inhibidores de la lipasa sensible a hormonas.
CA2526518A1 (en) 2003-06-12 2004-12-23 Novo Nordisk A/S 1-aryl-4-(aryloxycarbonyl)-piperazine derivatives for use as inhibitors of hormone sensitive lipase
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
FR2865205B1 (fr) 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866888B1 (fr) 2004-02-26 2006-05-05 Sanofi Synthelabo Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
FR2866884B1 (fr) 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
EP1882684B1 (en) * 2005-05-19 2014-12-10 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04261157A (ja) * 1990-09-27 1992-09-17 Hoechst Roussel Pharmaceut Inc 置換−４−アミノ−３−ピリジノール、その製造法および医薬としてのその使用
JPH09510974A (ja) * 1994-03-25 1997-11-04 バーテクス ファーマシューティカルズ インコーポレイテッド 多剤耐性のモディファイアーとしての新規カルバメートおよびウレア
JPH09511764A (ja) * 1995-01-11 1997-11-25 三進製藥株式會社 新規ピペラジン誘導体、その製造方法及びそれを含有する組成物
JP2001503778A (ja) * 1996-11-13 2001-03-21 バーテックス ファーマシューティカルズ インコーポレイテッド 神経栄養因子と組み合わせてｆｋｂｐ１２に関するアフィニティを有する化合物を用いて神経突起の成長を刺激する方法および組成物
JP2002541109A (ja) * 1999-04-01 2002-12-03 ファイザー・プロダクツ・インク ソルビトールデヒドロゲナーゼ阻害薬としてのアミノピリミジン

Also Published As

Publication number Publication date
PL2607362T3 (pl) 2015-05-29
US7919494B2 (en) 2011-04-05
SI1849773T1 (sl) 2013-12-31
CA2598294C (en) 2011-10-18
TW200940526A (en) 2009-10-01
TWI385152B (zh) 2013-02-11
BRPI0608205B1 (pt) 2019-02-05
ES2433290T3 (es) 2013-12-10
EP2607362A1 (en) 2013-06-26
PL1849773T3 (pl) 2014-03-31
US20080306046A1 (en) 2008-12-11
TW200640864A (en) 2006-12-01
AU2006215080B2 (en) 2011-03-10
KR101063663B1 (ko) 2011-09-07
CN101160287A (zh) 2008-04-09
WO2006088075A1 (ja) 2006-08-24
TWI359140B (enExample) 2012-03-01
US7915261B2 (en) 2011-03-29
IL184998A (en) 2014-11-30
RU2009121774A (ru) 2010-09-27
KR101063585B1 (ko) 2011-09-07
PT1849773E (pt) 2013-12-04
RU2009121775A (ru) 2010-09-27
US7919495B2 (en) 2011-04-05
RU2007134441A (ru) 2009-03-27
KR20070107122A (ko) 2007-11-06
PT2607362E (pt) 2015-03-16
US20100009972A1 (en) 2010-01-14
AU2010202347B2 (en) 2011-06-02
SI2607362T1 (sl) 2015-03-31
RU2376289C2 (ru) 2009-12-20
EP2607362B1 (en) 2014-12-31
MX2007010076A (es) 2007-10-16
AU2010202347A1 (en) 2010-07-01
AU2010202348B2 (en) 2011-07-21
KR20090078841A (ko) 2009-07-20
AU2010202348A1 (en) 2010-07-01
BRPI0608205A2 (pt) 2009-12-01
RU2408580C2 (ru) 2011-01-10
AU2006215080A1 (en) 2006-08-24
NO20074697L (no) 2007-11-16
CA2598294A1 (en) 2006-08-24
EP1849773A4 (en) 2011-06-15
CY1116348T1 (el) 2017-02-08
IL184998A0 (en) 2007-12-03
JPWO2006088075A1 (ja) 2008-07-03
BRPI0608205B8 (pt) 2021-05-25
CN101160287B (zh) 2011-08-03
DK2607362T3 (en) 2015-01-19
TWI385164B (zh) 2013-02-11
CY1114709T1 (el) 2016-10-05
EP1849773A1 (en) 2007-10-31
TW200940507A (en) 2009-10-01
US20100009971A1 (en) 2010-01-14
EP1849773B1 (en) 2013-10-16
DK1849773T3 (da) 2013-11-04
KR20090077855A (ko) 2009-07-15
ES2528674T3 (es) 2015-02-11
KR101065979B1 (ko) 2011-09-19
RU2408581C2 (ru) 2011-01-10

Similar Documents

Publication Publication Date Title
JP4702361B2 (ja) ピリジル非芳香族含窒素ヘテロ環−１−カルボン酸エステル誘導体
JPWO2008023720A1 (ja) ウレア化合物又はその塩
CN108025002B (zh) 含有六元氮杂杂环的δ阿片受体调节化合物、其使用和制备方法
CN101466378A (zh) 用于治疗骨关节炎和骨关节病的哌啶衍生物
HK1254498B (en) 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
KR20040030114A (ko) 환상 아민 화합물

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100727

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101201

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110221

R150 Certificate of patent or registration of utility model

Ref document number: 4702361

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140318

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140318

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140318

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250